Form 4: Evoke Pharma Director Sells Shares Under 10b5-1 Plan

Evoke Pharma Director Roger M. Klein reported the sale of 9,000 shares of common stock on November 6, 2025, pursuant to a Rule 10b5-1 trading plan.

Summary

• Roger M. Klein, a Director and 10% Owner of Evoke Pharma Inc. (EVOK), sold a total of 9,000 shares of common stock.
• The transactions occurred on November 6, 2025.
• One sale involved 5,000 shares at a weighted average price of $10.657 per share, with prices ranging from $10.65 to $10.66.
• Another sale involved 4,000 shares at a price of $10.65 per share.
• The sales were made directly by Mr. Klein.
• Following these transactions, Mr. Klein indirectly beneficially owns 29,000 shares through his Roth Individual Retirement Account (IRA) and 125,000 shares through the Krieger Charitable Trust, where he is the sole trustee.
• The filing indicates that the transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While insider selling can be a negative signal, the presence of a 10b5-1 plan suggests a pre-planned liquidity event rather than a reaction to new, adverse information, thus mitigating the negative impact.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, which suggests the transactions were pre-scheduled and not based on new, non-public information, potentially mitigating negative market perception.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it reduces the insider's direct stake in the company.

Risks

• Potential negative market sentiment if investors interpret the insider sale as a lack of confidence, despite the 10b5-1 plan.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• Mr. Klein disclaims beneficial ownership of the securities reported, except to the extent of his pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that he is a beneficial owner of the securities.

Industry Context

This insider transaction report is specific to Evoke Pharma and does not provide broader industry context. Insider sales are a routine part of market activity, and their interpretation often depends on the specific circumstances, such as the presence of a 10b5-1 plan.

Related Party Transactions

• The sales were conducted by Roger M. Klein, a Director and 10% Owner, making these related party transactions.
• A portion of the remaining beneficial ownership is held indirectly through the Krieger Charitable Trust, for which Mr. Klein is the sole trustee.

Stakeholder Impact

• Shareholders may monitor insider transactions for insights into management's confidence. The 10b5-1 plan context is important for their interpretation.

Key Dates

Recommendation

A single Form 4 filing, even for a director and 10% owner, typically does not warrant a strong buy or sell recommendation, especially when the transaction is executed under a Rule 10b5-1 plan. Such plans indicate pre-scheduled sales for personal financial planning rather than a reaction to new company developments. Investors should consider this information as part of a broader analysis of the company's fundamentals and market conditions.

Keywords

Evoke Pharma, EVOK, Insider Trading, Form 4, Stock Sale, Director, 10% Owner, 10b5-1 Plan